Here are the 10-Q quarterly reports from Apnimed, Inc. (APMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow APMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APMD filings page.
Apnimed, Inc. (APMD) reports a sharp move to profitability in the quarter and six months ended June 30, 2026, driven by one‑time gains tied to its sleep‑disorders joint venture and balance‑sheet transactions rather than ongoing operations. Related‑party revenue for the first half of 2026 rose to $96.9 million from $20.2 million a year earlier, and income from operations turned to a $56.3 million profit from a $33.0 million loss. Net income for the first half was $193.7 million versus a $98.1 million loss in 2025, primarily reflecting an $85.4 million gain on the sale of its equity‑method interest in Shionogi‑Apnimed Sleep Science (SASS) and a $57.1 million gain from reversal of a deposit liability.
Operating cash flow remained negative at $(37.9) million for the six months, but cash and cash equivalents increased to $172.8 million at June 30, 2026, boosted by the $100 million SASS sale, new debt and preferred equity. Management states that existing cash plus IPO proceeds will fund operations for at least twelve months from issuance. The company continues to focus on its lead obstructive sleep apnea candidate Oxnimbi, with significant dependency and typical late‑stage biotech risks highlighted in its risk summary.